Dmd Gene Mutation Amenable To Exon 51 Skipping Therapeutics
1. Exondys 51 patent expiration
Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)-(iii) in patients having a confirmed mutation of the dmd ge...
EXONDYS 51's oppositions filed in EPO
EXONDYS 51 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US9243245 | SAREPTA | Means and methods for counteracting muscle disorders |
Oct, 2028
(2 years from now) | |
| US9018368 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US10781451 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486907 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US10533174 | SAREPTA | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10364431 | SAREPTA | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| USRE47751 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(7 months ago) | |
| US9506058 | SAREPTA | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| US10337003 | SAREPTA | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| USRE48468 | SAREPTA | Means and methods for counteracting muscle disorders |
Oct, 2028
(2 years from now) | |
| USRE47769 | SAREPTA | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
